Nikos Pantazis

List of Publications by Year
in descending order

74	3,052	218381	161609
papers	citations	26	54
		h-index	g-index

75	75	75	4850
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comparison of Evidence of Treatment Effects in Randomized and Nonrandomized Studies. JAMA - Journal of the American Medical Association, 2001, 286, 821.	3.8	730
2	Response to combination antiretroviral therapy: variation by age. Aids, 2008, 22, 1463-1473.	1.0	188
3	Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds <200, <350, and <500 Cells/mm3: Assessment of Need Following Changes in Treatment Guidelines. Clinical Infectious Diseases, 2011, 53, 817-825.	2.9	180
4	Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection. PLoS Pathogens, 2016, 12, e1005661.	2.1	152
5	High levels of postmigration HIV acquisition within nine European countries. Aids, 2017, 31, 1979-1988.	1.0	105
6	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clinical Infectious Diseases, 2018, 66, 893-903.	2.9	105
7	Using CD4 Data to Estimate HIV Incidence, Prevalence, and Percent of Undiagnosed Infections in the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 3-9.	0.9	93
8	Frequency and distribution of root filled teeth and apical periodontitis in a Greek population. International Endodontic Journal, 2005, 38, 105-111.	2.3	89
9	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. Clinical Infectious Diseases, 2013, 56, 888-897.	2.9	88
10	Quantitation of Human Immunodeficiency Virus Type 1 DNA Forms with the Second Template Switch in Peripheral Blood Cells Predicts Disease Progression Independently of Plasma RNA Load. Journal of Virology, 2002, 76, 10099-10108.	1.5	84
11	Gender Differences in HIV Progression to AIDS and Death in Industrialized Countries: Slower Disease Progression Following HIV Seroconversion in Women. American Journal of Epidemiology, 2008, 168, 532-540.	1.6	82
12	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per Î¼L in Europe and North America: a pooled cohort observational study. Lancet, The, 2010, 376, 340-345.	6.3	82
13	Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Aids, 2009, 23, 2029-2037.	1.0	64
14	Highly Active Antiretroviral Therapy Interruption. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 554-561.	0.9	62
15	Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. Aids, 2004, 18, 1697-1705.	1.0	56
16	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV,the, 2015, 2, e335-e343.	2.1	52
17	The optimal home blood pressure monitoring schedule based on the Didima outcome study. Journal of Human Hypertension, 2010, 24, 158-164.	1.0	50
18	Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration. International Journal of Antimicrobial Agents, 2019, 53, 294-301.	1.1	46

#	Article	IF	Citations
19	Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. Aids, 2004, 18, 2261-2267.	1.0	44
20	HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors. BMC Medicine, 2019, 17, 4.	2.3	43
21	Predictors of <scp>CD</scp>4 cell recovery following initiation of antiretroviral therapy among <scp>HIV</scp>â€1 positive patients with wellâ€estimated dates of seroconversion. HIV Medicine, 2018, 19, 184-194.	1.0	41
22	Factors associated with short-term changes in HIV viral load and CD4+ cell count in antiretroviral-naive individuals. Aids, 2014, 28, 1351-1356.	1.0	32
23	Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. Lancet HIV,the, 2014, 1, e119-e126.	2.1	32
24	Differences in HIV Natural History among African and Non-African Seroconverters in Europe and Seroconverters in Sub-Saharan Africa. PLoS ONE, 2012, 7, e32369.	1.1	30
25	CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. Aids, 2010, 24, 2697-2704.	1.0	29
26	A randomized trial comparing concise and standard consent forms in the START trial. PLoS ONE, 2017, 12, e0172607.	1.1	28
27	Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. Aids, 2007, 21, 1283-1291.	1.0	26
28	The effect of antiretroviral treatment of different durations in primary HIV infection. Aids, 2008, 22, 2441-2450.	1.0	26
29	The Influence of Different Power Settings of Nd:YAG Laser Irradiation, Bioglass and Combination to the Occlusion of Dentinal Tubules. Photomedicine and Laser Surgery, 2013, 31, 54-58.	2.1	23
30	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. Aids, 2015, 29, 2323-2333.	1.0	21
31	Bivariate modelling of longitudinal measurements of two human immunodeficiency type 1 disease progression markers in the presence of informative drop-outs. Journal of the Royal Statistical Society Series C: Applied Statistics, 2005, 54, 405-423.	0.5	20
32	Elevated Serum Levels of Soluble Immune Activation Markers Are Associated with Increased Risk for Death in HAART-Naive HIV-1â€"Infected Patients. AIDS Patient Care and STDs, 2003, 17, 147-153.	1.1	16
33	Uptake of Combination Antiretroviral Therapy and HIV Disease Progression According to Geographical Origin in Seroconverters in Europe, Canada, and Australia. Clinical Infectious Diseases, 2012, 54, 111-118.	2.9	16
34	Emergency care provided in a Greek dental school and analysis of the patientsâ€™ demographic characteristics: a prospective study. International Dental Journal, 2016, 66, 280-286.	1.0	16
35	Reference curves for <scp>CD</scp>4 Tâ€cell count response to combination antiretroviral therapy in <scp>HIV</scp>â€1â€infected treatmentâ€naÃ¯ve patients. HIV Medicine, 2017, 18, 33-44.	1.0	16
36	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. Clinical Infectious Diseases, 2020, 71, 2905-2916.	2.9	16

#	Article	IF	Citations
37	HIV incidence in the Estonian population in 2013 determined using the HIV‐1 limiting antigen avidity assay. HIV Medicine, 2018, 19, 33-41.	1.0	15
38	Determining the likely place of HIV acquisition for migrants in Europe combining subject-specific information and biomarkers data. Statistical Methods in Medical Research, 2019, 28, 1979-1997.	0.7	15
39	What do the changing patterns of comorbidity burden in people living with HIV mean for long‐term management? Perspectives from European HIV cohorts. HIV Medicine, 2020, 21, 3-16.	1.0	15
40	Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. Aids, 2017, 31, 835-846.	1.0	14
41	Longitudinal and Time-to-Drop-Out Joint Models Can Lead to Seriously Biased Estimates When the Drop-Out Mechanism is at Random. Biometrics, 2019, 75, 58-68.	0.8	14
42	Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination. Vaccines, 2022, 10, 285.	2.1	13
43	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 311-318.	0.9	12
44	Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy. Aids, 2019, 33, 1645-1655.	1.0	12
45	Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration. PLoS ONE, 2013, 8, e71174.	1.1	12
46	Rates and Determinants of Virologic and Immunological Response to HAART Resumption After Treatment Interruption in HIV-1 Clinical Practice. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 492-498.	0.9	11
47	Changes in T Cell Receptor Excision DNA Circle (TREC) Levels in HIV Type 1-Infected Subjects Pre- and Post-Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 47-54.	0.5	10
48	Analyzing Longitudinal Data in the Presence of Informative Dropout: The Jmre1 Command. The Stata Journal, 2010, 10, 226-251.	0.9	10
49	The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. Aids, 2016, 30, 879-888.	1.0	9
50	Discriminating Between Premigration and Postmigration HIV Acquisition Using Surveillance Data. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 117-124.	0.9	9
51	Potential adjustment methodology for missing data and reporting delay in the HIV Surveillance System, European Union/European Economic Area, 2015. Eurosurveillance, 2018, 23, .	3.9	9
52	Disease progression and mortality with untreated HIV infection: evidence synthesis of HIV seroconverter cohorts, antiretroviral treatment clinical cohorts and population‐based survey data. Journal of the International AIDS Society, 2021, 24, e25784.	1.2	8
53	Robustness of a parametric model for informatively censored bivariate longitudinal data under misspecification of its distributional assumptions: A simulation study. Statistics in Medicine, 2007, 26, 5473-5485.	0.8	7
54	The permanent deformation of the self‐adjusting files when used in canals of extracted teeth. International Endodontic Journal, 2013, 46, 863-869.	2.3	6

#	Article	IF	Citations
55	A method to estimate the size and characteristics of HIV-positive populations using an individual-based stochastic simulation model. Epidemiology, 2015, 27, 1.	1.2	6
56	Ten-year survival outcomes of patients with potentially resectable gastric cancer: impact of clinicopathologic and treatment-related risk factors. Annals of Gastroenterology, 2018, 32, 99-106.	0.4	6
57	Central-line-associated bloodstream infections, multi-drug-resistant bacteraemias and infection control interventions: a 6-year time-series analysis in a tertiary care hospital in Greece. Journal of Hospital Infection, 2022, 123, 27-33.	1.4	6
58	CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. Journal of Antimicrobial Chemotherapy, 2017, 72, 2862-2868.	1.3	5
59	Caroticoclinoid Bar: A Systematic Review and Meta-Analysis of Its Prevalence and Potential Implications in Cerebrovascular and Skull Base Surgery. World Neurosurgery, 2019, 124, 267-276.	0.7	5
60	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. Aids, 2019, 33, 327-337.	1.0	5
61	Birth order and memories of traumatic and family experiences in Greek patients with borderline personality disorder versus patients with other personality disorders. Bulletin of the Menninger Clinic, 2016, 80, 234-254.	0.3	4
62	The HIV patient profile in 2013 and 2003: Results from the Greek AMACS cohort. PLoS ONE, 2018, 13, e0203601.	1.1	4
63	Preliminary Data of a Quantitative Point of Care Test for SARS-CoV-2 Antibodies From Greece. In Vivo, 2020, 34, 3039-3045.	0.6	4
64	HIV continuum of care: expanding scope beyond a cross-sectional view to include time analysis: a systematic review. BMC Public Health, 2021, 21, 1699.	1.2	4
65	HIV continuum of care: bridging cross-sectional and longitudinal analyses. Aids, 2022, 36, 583-591.	1.0	3
66	Association between consumption of antibiotics, infection control interventions and Clostridioides difficile infections: Analysis of six-year time-series data in a tertiary-care hospital in Greece. Infection, Disease and Health, 2022, 27, 119-128.	0.5	3
67	Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals. Journal of Chemotherapy, 2012, 24, 38-47.	0.7	2
68	Treatment Modifications and Treatment-Limiting Toxicities or Side Effects: Risk Factors and Temporal Trends. AIDS Research and Human Retroviruses, 2015, 31, 707-717.	0.5	2
69	Influence of Laser Irradiation Settings, during Diode-Assisted Endodontics, on the Intraradicular Adhesion of Self-Etch and Self-Curing Luting Cement during Restoration—An Ex Vivo Study. Materials, 2022, 15, 2531.	1.3	2
70	Six-Year Time-Series Data on Multidrug-Resistant Bacteremia, Antibiotic Consumption, and Infection Control Interventions in a Hospital. Microbial Drug Resistance, 2022, 28, 806-818.	0.9	2
71	Performance of parametric survival models under non-random interval censoring: A simulation study. Computational Statistics and Data Analysis, 2013, 63, 16-30.	0.7	1
72	Misspecifying the covariance structure in a linear mixed model under MAR drop—out. Statistics in Medicine, 2020, 39, 3027-3041.	0.8	1

#	Article	IF	Citations
73	Rejoinder to â€œBiased Estimation With Shared Parameter Models in the Presence of Competing Dropout Mechanismsâ€• Biometrics, 2022, 78, 407-408.	0.8	0
74	Effectiveness of fissure sealants on initial caries lesions (ICDAS 1-3) of permanent molars: A 4-year follow-up. European Journal of Paediatric Dentistry, 2021, 22, 180-188.	0.4	0